<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1">

MUMS (Minor Use Major Species) Status secured for new pipeline product in the US and Europe

TriviumVet have received MUMS status for a new product in both the US and EU markets. The molecule is an exciting therapeutic which will have a big impact on the quality of life of pets across the US and European market. Clinical trials are set to commence in Q3 2020.